ArticleCureus2025
Oncocytic Carcinoma: A Rare Hormone-Producing Tumor.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncocytic Adrenocortical Carcinoma with Somatic Pathogenic Variants ofDiagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncocytic adrenocortical carcinoma (OACC) is a rare type of malignancy that affects the adrenal cortex. We describe the case of a 68‑year‑old woman with months of refractory hypertension, hypokalemia, headaches, night sweats, and palpitations. Computed tomography revealed a 113 mm left adrenal mass displacing the pancreatic tail and spleen. After a multidisciplinary review, she underwent open adrenalectomy. The 355 g tumor was well circumscribed; histology showed abundant eosinophilic oncocytes arranged in nests and trabeculae, 36 mitoses per 50 high‑power fields (including atypical figures), necrosis, and venous invasion, and the Ki‑67 index was 10%. These findings satisfied major and minor Lin-Weiss-Bisceglia criteria, confirming OACC. Immunohistochemistry was positive for calretinin, Melan‑A, synaptophysin, and inhibin, consistent with adrenocortical origin. Postoperatively, hypertension and potassium levels normalized with reduced antihypertensive therapy; she commenced steroid replacement and adjuvant mitotane. At early follow‑up, she remained clinically stable and disease‑free. This case highlights the importance of considering OACC in patients with large adrenal masses and resistant hypertension, demonstrates the value of multidisciplinary management and definitive surgery, and contributes to the limited evidence guiding adjuvant therapy for this uncommon tumor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.